Potentiation of mutant CFTR Cl- channel currents by the naturally occurring stilbene compound resveratrol

Pharmazie

Volumn 68, Issue 11, 2013, Pages 877-881

  Yu, Bo ^a   Zhang, Yaofang ^a   Sui, Yujie ^b   Yang, Shuang ^a   Luan, Jian ^a   Wang, Xue ^a   Tonghui, Ma ^a,b   Yang, Hong ^a  

^a LIAONING NORMAL UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PILOCARPINE; RESVERATROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL STIMULATION; CHLORIDE CURRENT; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FLUORESCENCE; MOUSE; MUTANT; NONHUMAN; PATCH CLAMP; SECRETION (PROCESS); SHORT CIRCUIT CURRENT; TRACHEA; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IODIDES; MUTATION; PATCH-CLAMP TECHNIQUES; RATS; RATS, INBRED F344; STILBENES; SUBMUCOUS PLEXUS;

EID: 84888988441     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.3602     Document Type: Article

References (35)

1. Alexander NS, Hatch N, Zhang S, Skinner D, Fortenberry J, Sorscher EJ, Woodworth BA (2011) Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope 121: 1313-1319.
2. Ballard ST, Spadafora D (2007) Fluid secretion by submucosal glands of the tracheobronchial airways. Respir Physiol Neurobiol 159: 271-277.
3. Banales JM, Prieto J and Medina JF (2006) Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol 12: 3496-3511.
4. Blumenstein I, Keseru B, Wolter F, Stein J (2005) The chemopreventive agent RES stimulates cyclic AMP-dependent chloride secretion in vitro. Clin Cancer Res 11: 5651-5656.
5. Bradamante S, Barenghi L, Villa A (2004) Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22: 169-188.
6. Cheng SH, Gregory RJ, Marshall J, Paul S, SouzaDW, White GA, O'Riordan CR, Smith AE (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
7. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354 (6354): 526-528.
8. Galietta LV, Jayaraman S, Verkman AS (2001) Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-1742.
9. Greger R (2000) Role of CFTR in the colon. Annu Rev Physiol 62: 467-491.
10. Gregory RJ, Rich DP, Cheng SH, Souza DW, Paul S, Manavalan P, Anderson MP, Welsh MJ, Smith AE (1991) Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. Mol Cell Biol 11: 3886-3893.
11. He CY, Zhang HJ, Su ZM, Zhou JS, Yang H, Ma TH (2004) Synthesis and characterization of a small molecule thiazolidinone CFTR chloride channel inhibitor. Chem Res Chinese U 20: 334-337.
12. He Q, Zhu JX, Xing Y, Tsang LL, Yang N, Rowlands DK, ChungYW, Chan HC (2005) Tetramethylpyrazine stimulates cystic fibrosis transmembrane conductance regulator-mediated anion secretion in distal colon of rodents. World J Gastroenterol 11: 4173-4179.
13. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
14. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL (2010) Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68: 593-601.
15. Kerem B, Rommens KM, Buchanan D, Mardiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic gene, genetic analysis. Science 245: 1073-1080.
16. Kopeikin Z, Sohma Y, Li M, Hwang TC (2010) On the mechanism of CFTR inhibition by a thiazolidinone derivative. J Gen Physiol. 136: 659-671.
17. Kunzelmann K (1999) The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 137: 1-70.
18. Kutuk O, Basaga H (2007) Apoptosis signalling by 4-hydroxynonenal: a role for JNK-c-Jun/AP-1 pathway. Redox Rep 12: 30-34.
19. MaTH, Thiagarajah JR,Yang H, Sonawane ND, Folli C, Galietta LJ,Verkma AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658.
20. Nakata R, Takahashi S, Inoue H (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35: 273-279.
21. Nonomura S, Kanagawa H, Makimoto A (1963) Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum cuspidatum SIEB. et ZUCC.). Yakugaku Zasshi 83: 988-990.
22. Pedemonte N, Lukacs, GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571.
23. Pier GB (2012) The challenges and promises of new therapies for cystic fibrosis. J Exp Med 209: 1235-1239.
24. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
25. Riordan JR, Rommens JM, Kerem D, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Rsui L (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
26. - channel function. Am J Physiol Lung Cell Mol Physiol 297: 1131-1140.
27. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS (2001) Molecular mechanisms underlying chemopreventive activities of antiinflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481: 243-268.
28. Takaoka M (1940) Of the phenolic substances of white hellebore (Veratrum grandiflorum LOES. fil.). J Fac Sci Hokkaido Imperial University 3: 1-16.
29. Toczyłowska-Mamińska R, Dołowy K (2012) Ion transporting proteins of human bronchial epithelium. J Cell Biochem 113: 426-432.
30. Tyagi A, Singh RP,Agarwal C, Siriwardana S, Sclafani R, Agarwal R (2005) Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26: 1978-1987.
31. Ulrich S, Wolter F, Stein JM (2005) Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res. 49: 452-461.
32. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447.
33. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Tadde A, Folli C, Pedemonte N, Galietta LJ, Verkman AS (2003) Nanomolar affinity small molecule correctors of defective {Delta}F508-CFTR chloride channel gating. J Biol Chem 278: 35079-35085.
34. Yang S, Yu B, Sui YJ, Zhang YF, Wang X, Hou SG, Ma TH, Yang H (2103) CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol. Pharmazie doi: 10.1691/ph.2013.3548.
35. Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, Galietta LJ (2002) Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 137: 504-512.